Lung Cancer in Indonesia

Asmara, Oke Dimas; Tenda, Eric Daniel; Singh, Gurmeet; Pitoyo, Ceva Wicaksono; Rumende, Cleopas Martin; Rajabto, Wulyo; Ananda, Nur Rahmi; Trisnawati, Ika; Budiyono, Eko; Thahadian, Harik Firman; Boerma, E. Christiaan; Faisal, Achmad; Hutagaol, David; Soeharto, Wuryantoro; Radityamurti, Fahmi; Marfiani, Erika; Romadhon, Pradana Zaky; Kholis, Fathur Nur; Suryadinata, Hendarsyah; Soeroto, Arto Yuwono; Gondhowiardjo, Soehartati A.; van Geffen, Wouter H.

doi:10.1016/j.jtho.2023.06.010

Cited by 3 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer was the highest incidence in the 50-70 age group, according to data analysis from the national referral hospital in Indonesia's 2008-2012 cancer registry (Asmara et al, 2023). Significant differences have been seen in the incidence and demographic distribution of lung cancer between nations; these variations are influenced by factors such as economic development level and tobacco smoking rates.…”

Section: Epidemiologymentioning

confidence: 99%

“…After the identification of high-risk nodules, to confirm the diagnosis, determine the course of treatment, and forecast the patient's prognosis, additional testing may be required (Asmara et al, 2023). CT filters are a more successful radiologic assessment for the location of cellular breakdown in the lungs, regardless of whether chest radiographs are the significant technique used to analyze thought cellular breakdown in the lungs.…”

Section: Further Analysismentioning

confidence: 99%

“…Only difficult and high-risk cases should be treated with an open thoracotomy. Another technique is mastectomy with video-assisted thoracoscopic surgery, often known as thoracotomy, which is reserved for extremely specific stage IV cases due to its shorter hospital stay and lower death rate than open thoracotomy (Asmara et al, 2023).…”

Section: Oversight Operationmentioning

confidence: 99%

“…Chemotherapy can be used as a postsurgical adjuvant therapy or as a neoadjuvant for lung cancer in its early stages. In order to provide palliative care or extend survival, the management strategy for lung cancer is multimodality, combining other modalities (radiation) with systemic treatment options (chemotherapy, immunotherapy, and targeted therapy) (Asmara et al, 2023).…”

Section: Systemic Interventionmentioning

confidence: 99%

“…Platinum-based chemotherapy, for example, cisplatin or carboplatin in blend with paclitaxel, docetaxel, gemcitabine, pemetrexed (for adenocarcinoma just), and vinorelbine, is prompted as the first-line chemotherapy routine. Original (gefitinib and erlotinib) and second-age (afatinib) EGFR tyrosine kinase inhibitors (TKI) are prompted for patients with cutting edge non-little cell cellular breakdown in the lungs (NSCLC) that have targetable drivers for NSCLC with EGFR change (Asmara et al, 2023).…”

Section: Systemic Interventionmentioning

confidence: 99%

See 4 more Smart Citations

Overview of Lung Cancer

Indira Medika

2023

KESANS

View full text Add to dashboard Cite

The two main types of lung cancer are small cell carcinoma and non-small cell carcinoma. Lung cancer is a primary bronchogenic carcinoma. Patients who are diagnosed with lung cancer typically exhibit symptoms like hemoptysis, dyspnea, chronic cough, chest pain, or weight loss. Since the onset of symptoms typically indicates that a patient's stage has already progressed, screening with low-dose chest CT (LDCT) exams is advised for high-risk patients. Cytology and core biopsy specimens are the main sources of the diagnosis for these patients. Staging, histology, genetic, and immunotherapy biomarker tests form the basis of the treatment. The most often used pharmacological therapies include radiotherapy, adjuvant platinum-based chemotherapy, surgery, which might involve mediastinal lymph node dissection or lymph node sampling, as well as total removal of the tumor (typically stages I and II). Currently, meanwhile, immunotherapy is the most advanced form of treatment for NSCLC that is oncogenic driver negative

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Further Analysismentioning

confidence: 99%

Section: Oversight Operationmentioning

confidence: 99%

Section: Systemic Interventionmentioning

confidence: 99%

Section: Systemic Interventionmentioning

confidence: 99%

See 3 more Smart Citations

Overview of Lung Cancer

Indira Medika

2023

KESANS

View full text Add to dashboard Cite

show abstract

Stage III NSCLC treatment options: too many choices

Asmara,

Hardavella,

Ramella

et al. 2024

Breathe

View full text Add to dashboard Cite

Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour–node–metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.

show abstract

Effect of black sticky rice tape and purple sweet potato formulation on organoleptic properties and anthocyanin content of sweet purple mochi as a high anthocyanin snack to prevent cancer

Fauziyah,

Salsabil,

Sulaeman

et al. 2024

Healthc Low-resour S

View full text Add to dashboard Cite

Cancer is one of the second leading causes of death worldwide. It is estimated that by 2030, cancer incidence could reach 26 million people, and 17 million of them will die because of cancer. Free radicals in the body can cause cancer, so it is very important to consume foods rich in antioxidants, such as black glutinous rice tape and purple sweet potato, because the human body cannot naturally make antioxidants. The study aimed to determine the effect of black sticky rice and purple sweet potato formulations on organoleptic properties (color, aroma, taste, texture, and overall) and the anthocyanin content in sweet purple mochi. The method used a hedonic test to determine the level of liking and UV-VIS spectrophotometry combined with differential pH to determine anthocyanin levels. Thirty participants were students from Nutrition Department, Politeknik Kesehatan Kemenkes Bandung. The results showed significant aroma, taste, and overall p<0.05 differences. F3 was the most preferred formulation, containing 11.2 mg of anthocyanins per 70 gram. There were significant effects and differences in the formulation of black sticky rice tape and purple sweet potato on organoleptic properties (aroma, taste, and overall). The anthocyanin content in the product can fulfill the adequacy of anthocyanins in a day, so this product can be used as a snack to prevent cancer.

show abstract

Lung Cancer in Indonesia

Cited by 3 publications

References 15 publications

Overview of Lung Cancer

Overview of Lung Cancer

Stage III NSCLC treatment options: too many choices

Effect of black sticky rice tape and purple sweet potato formulation on organoleptic properties and anthocyanin content of sweet purple mochi as a high anthocyanin snack to prevent cancer

Contact Info

Product

Resources

About